| Figure 1‑1: Cardiac Surgery Market Share Ranking by Segment, U.S., 2022 (1 of 5) |
| Figure 1‑2: Cardiac Surgery Market Share Ranking by Segment, U.S., 2022 (2 of 5) |
| Figure 1‑3: Cardiac Surgery Market Share Ranking by Segment, U.S., 2022 (3 of 5) |
| Figure 1‑4: Cardiac Surgery Market Share Ranking by Segment, U.S., 2022 (4 of 5) |
| Figure 1‑5: Cardiac Surgery Market Share Ranking by Segment, U.S., 2022 (5 of 5) |
| Figure 1‑6: Companies Researched in This Report |
| Figure 1‑7: Factors Impacting the Cardiac Surgery Market by Segment, U.S. (1 of 5) |
| Figure 1‑8: Factors Impacting the Cardiac Surgery Market by Segment, U.S. (2 of 5) |
| Figure 1‑9: Factors Impacting the Cardiac Surgery Market by Segment, U.S. (3 of 5) |
| Figure 1‑10: Factors Impacting the Cardiac Surgery Market by Segment, U.S. (4 of 5) |
| Figure 1‑11: Factors Impacting the Cardiac Surgery Market by Segment, U.S. (5 of 5) |
| Figure 1‑12: Recent Events in the Cardiac Surgery Market, U.S., 2019 – 2023 |
| Figure 1‑13: Cardiac Surgery Procedures Covered (1 of 5) |
| Figure 1‑14: Cardiac Surgery Procedures Covered (2 of 5) |
| Figure 1‑15: Cardiac Surgery Procedures Covered (3 of 5) |
| Figure 1‑16: Cardiac Surgery Procedures Covered (4 of 5) |
| Figure 1‑17: Cardiac Surgery Procedures Covered (5 of 5) |
| Figure 1‑18: Procedure Codes Investigated |
| Figure 1‑19: Cardiac Surgery Markets Covered (1 of 3) |
| Figure 1‑20: Cardiac Surgery Markets Covered (2 of 3) |
| Figure 1‑21: Cardiac Surgery Markets Covered (3 of 3) |
| Figure 1‑22: Key Report Updates |
| Figure 1‑23: Version History |
| Figure 2‑1: Cardiac Surgery Market by Segment, Worst Case Scenario, U.S., 2019 – 2029 (US$M) (1 of 3) |
| Figure 2‑2: Cardiac Surgery Market by Segment, Worst Case Scenario, U.S., 2019 – 2029 (US$M) (2 of 3) |
| Figure 2‑3: Cardiac Surgery Market by Segment, Worst Case Scenario, U.S., 2019 – 2029 (US$M) (3 of 3) |
| Figure 2‑4: Cardiac Surgery Market by Segment, Base Case Scenario, U.S., 2019 – 2029 (US$M) (1 of 3) |
| Figure 2‑5: Cardiac Surgery Market by Segment, Base Case Scenario, U.S., 2019 – 2029 (US$M) (2 of 3) |
| Figure 2‑6: Cardiac Surgery Market by Segment, Base Case Scenario, U.S., 2019 – 2029 (US$M) (3 of 3) |
| Figure 2‑7: Cardiac Surgery Market by Segment, Best Case Scenario, U.S., 2019 – 2029 (US$M) (1 of 3) |
| Figure 2‑8: Cardiac Surgery Market by Segment, Best Case Scenario, U.S., 2019 – 2029 (US$M) (2 of 3) |
| Figure 2‑9: Cardiac Surgery Market by Segment, Best Case Scenario, U.S., 2019 – 2029 (US$M) (3 of 3) |
| Figure 4‑1: Tissue Heart Valve Devices by Company |
| Figure 4‑2: Mechanical Heart Valve Devices by Company |
| Figure 4‑3: Annuloplasty Repair Devices by Company |
| Figure 4‑4: Transcatheter Mitral Valve Repair Devices by Company |
| Figure 4‑5: Transcatheter Heart Valve Replacement Devices by Company |
| Figure 4‑6: Cerebral Embolic Protection Devices by Company |
| Figure 4‑7: Balloon Valvuloplasty Devices by Company |
| Figure 4‑8: On-Pump Coronary Artery Bypass Devices by Company (1 of 2) |
| Figure 4‑9: On-Pump Coronary Artery Bypass Devices by Company (2 of 2) |
| Figure 4‑10: Off-Pump Coronary Artery Bypass Devices by Company (1 of 2) |
| Figure 4‑11: Off-Pump Coronary Artery Bypass Devices by Company (2 of 2) |
| Figure 4‑12: Autotransfusion Devices by Company |
| Figure 4‑13: Endoscopic Vessel Harvesting Devices by Company |
| Figure 4‑14: Anastomosis Assist Devices by Company |
| Figure 4‑15: Transmyocardial Revascularization Devices by Company |
| Figure 4‑16: Ventricular Assist Devices by Company |
| Figure 4‑17: Intra-Aortic Balloon Pump Devices by Company |
| Figure 4‑18: Artificial Heart Replacement Devices by Company |
| Figure 4‑19: Remote Hemodynamic Monitoring System Devices by Company |
| Figure 4‑20: Patent Foramen Ovale Devices by Company |
| Figure 4‑21: Patent Ductus Arteriosus Closure Devices by Company |
| Figure 4‑22: Atrial & Ventricular Septal Defect Devices by Company |
| Figure 4‑23: Left Atrial Appendage Closure Devices by Company |
| Figure 4‑24: Preshaped Guidewires by Company |
| Figure 4‑25: Extracorporeal Membrane Oxygenation by Company (1 of 2) |
| Figure 4‑26: ECMO by Company (2 of 2) |
| Figure 4‑27: Temporary Pacing and Pressure Measurement Catheter by Company |
| Figure 4‑28: Class 2 Device Recall CryoValve SG Pulmonary Human Heart Valve |
| Figure 4‑29: Class 2 Device Recall PERCEVAL SUTURELESS HEART VALVE |
| Figure 4‑30: Class 2 Device Recall Hancock II T510 Bioprosthesis |
| Figure 4‑31: Class 2 Device Recall Mosaic 310 Bioprosthesis |
| Figure 4‑32: Class 2 Device Recall Cryovalve(R) SG Pulmonary Human Heart Valve |
| Figure 4‑33: Class 2 Device Recall, CryoLife |
| Figure 4‑34: Class 2 Device Recall Medtronic Open Pivot Aortic Valve Graft |
| Figure 4‑35: Class 2 Device Recall OnX Aortic Heart Valve |
| Figure 4‑36: Class 1 Device Recall, CryoLife |
| Figure 4‑37: Class 2 Device Recall Medtronic Simulus 850 Semi Rigid Ring/Band Accessory Kit |
| Figure 4‑38: Class 2 Device Recall Medtronic Simulus 750 Flexible Ring/Band Accessory Kit |
| Figure 4‑39: Class 2 Device Recall MitraClip" and TriClip" Delivery System(s) |
| Figure 4‑40: Class 2 Device Recall Abbott MitraClip XTR Clip Delivery System |
| Figure 4‑41: Class 2 Device Recall, Abbott |
| Figure 4‑42: Class 1 Device Recall Harmony Delivery Catheter System |
| Figure 4‑43: Class 1 Device Recall Lotus Edge Valve System |
| Figure 4‑44: Class 1 Device Recall Edwards Sapien 3 Ultra Delivery System |
| Figure 4‑45: Class 2 Device Recall Edwards SAPIEN 3 Transcatheter Heart Valve (THV) |
| Figure 4‑46: Class 2 Device Recall Quadroxi Pediatric |
| Figure 4‑47: Class 2 Device Recall QUADROXi Small Adult |
| Figure 4‑48: Class 2 Device Recall QUADROX i Neonatal |
| Figure 4‑49: Class 2 Device Recall QUADROXi Small Adult, BIOLINE Coated |
| Figure 4‑50: Class 2 Device Recall QUADROX iR |
| Figure 4‑51: Class 2 Device Recall Quadroxi Adult |
| Figure 4‑52: Class 2 Device Recall QUADROXi Small |
| Figure 4‑53: Class 2 Device Recall CAPIOX NX19 |
| Figure 4‑54: Class 2 Device Recall CAPIOX RX15 |
| Figure 4‑55: Class 2 Device Recall CAPIOX FX25 |
| Figure 4‑56: Class 2 Device Recall Affinity Fusion Oxygenator |
| Figure 4‑57: Class 1 Device Recall LifeSPARC Controller |
| Figure 4‑58: Class 1 Device Recall Affinity Pixie Oxygenator and Cardiotomy/Venous Reservoir with Balance Biosurface |
| Figure 4‑59: Class 2 Device Recall Capiox FX25 Advance Oxygenator |
| Figure 4‑60: Class 3 Device Recall ROTAFLOW Centrifugal Pump System |
| Figure 4‑61: Class 2 Device Recall ROTAFLOW Centrifugal Pump System |
| Figure 4‑62: Class 2 Device Recall Maquet/Getinge |
| Figure 4‑63: Class 3 Device Recall Smart Perfusion Pack |
| Figure 4‑64: Class 2 Device Recall Terumo Capiox NX19 Oxygenator |
| Figure 4‑65: Class 2 Device Recall |
| Figure 4‑66: Class 2 Device Recall ACROBAT V |
| Figure 4‑67: Class 2 Device Recall ACROBAT SUV |
| Figure 4‑68: Class 2 Device Recall ACROBATi |
| Figure 4‑69: Class 2 Device Recall CS Elite Fastpack |
| Figure 4‑70: Class 2 Device Recall CS Elite |
| Figure 4‑71: Class 2 Device Recall CS5/5 Fastpacks |
| Figure 4‑72: Class 2 Device Recall Cell Saver |
| Figure 4‑73: Class 2 Device Recall High Speed Cell Saver |
| Figure 4‑74: Class 2 Device Recall CSE Set |
| Figure 4‑75: Class 2 Device Recall CATSmart Autotransfusion |
| Figure 4‑76: Class 2 Device Recall CATSmart Vacuum Pump |
| Figure 4‑77: Class 2 Device Recall VASOVIEW HEMOPRO |
| Figure 4‑78: Class 2 Device Recall VASOVIEW HEMOPRO 2 |
| Figure 4‑79: Class 2 Device Recall Cardica CPort xA PLUS Anastomosis System |
| Figure 4‑80: Class 2 Device Recall HeartWare" Ventricular Assist Device (HVAD") System |
| Figure 4‑81: Class 1 Device Recall Impella RP Flex with SmartAssist |
| Figure 4‑82: Class 1 Device Recall Impella LD |
| Figure 4‑83: Class 1 Device Recall Impella CP with SmartAssist |
| Figure 4‑84: Class 1 Device Recall Impella 5.0 |
| Figure 4‑85: Class 1 Device Recall Impella 2.5 |
| Figure 4‑86: Class 1 Device Recall Impella CP |
| Figure 4‑87: Class 2 Device Recall HeartWare |
| Figure 4‑88: Class 1 Device Recall Heartware HVAD |
| Figure 4‑89: Class 1 Device Recall HeartWare HVAD Pump Implant Kit |
| Figure 4‑90: Class 2 Device Recall HeartWare Ventricular Assist Device (HVAD) System |
| Figure 4‑91: Class 2 Device Recall HeartWare HVAD System |
| Figure 4‑92: Class 2 Device Recall HeartMate Touch Communication System |
| Figure 4‑93: Class 2 Device Recall TandemHeart Pump |
| Figure 4‑94: Class 1 Device Recall HVAD Pump Implant Kit |
| Figure 4‑95: Class 1 Device Recall HVAD Pump Outflow Graft |
| Figure 4‑96: Class 2 Device Recall HeartMate 3 Left Ventricular Assist System |
| Figure 4‑97: Class 2 Device Recall HeartMate Left Ventricular Assist System |
| Figure 4‑98: Class 2 Device Recall HeartMate Outflow Graft |
| Figure 4‑99: Class 1 Device Recall Cardiosave Rescue IntraAortic Balloon Pump (IABP) |
| Figure 4‑100: Class 1 Device Recall Cardiosave Rescue IntraAortic Balloon Pump (IABP) |
| Figure 4‑101: Class 1 Device Recall Cardiosave Hybrid IntraAortic Balloon Pump (IABP) |
| Figure 4‑102: Class 1 Device Recall Cardiosave Hybrid IntraAortic Balloon Pump (IABP) |
| Figure 4‑103: Class 2 Device Recall Cardiosave Rescue |
| Figure 4‑104: Class 2 Device Recall Safety Disk |
| Figure 4‑105: Class 2 Device Recall Cardiosave Rescue |
| Figure 4‑106: Class 2 Device Recall Cardiosave Hybrid |
| Figure 4‑107: Class 1 Device Recall Cardiosave Hybrid IntraAortic Balloon Pump (IABP) |
| Figure 4‑108: Class 1 Device Recall Arrow AutoCAT2 |
| Figure 4‑109: Class 1 Device Recall Arrow AC3 Optimus |
| Figure 4‑110: Class 1 Device Recall AutoCAT IABP Series |
| Figure 4‑111: Class 1 Device Recall Arrow AutoCAT2 |
| Figure 4‑112: Class 1 Device Recall AC3 Series IABP System |
| Figure 4‑113: Class 2 Device Recall SynCardia temporary Total Artificial Heart System |
| Figure 4‑114: Class 2 Device Recall CardioMEMS |
| Figure 4‑115: Class 2 Device Recall CardioMEMSTM HF System Hospital Electronics System (HES) |
| Figure 4‑116: Class 2 Device Recall CardioMEMSTM HF System Patient Electronics System (PES) |
| Figure 4‑117: Class 2 Device Recall Gore Cardioform Septal Occluder |
| Figure 4‑118: Class 2 Device Recall GORE CARDIOFORM SEPTAL OCCLUDER |
| Figure 4‑119: Class 2 Device Recall GORE CARDIOFORM ASD Occluder |
| Figure 4‑120: Class 2 Device Recall Lunderquist Ring Torque Wire Guide |
| Figure 4‑121: Class 1 Device Recall Medtronic Confida Expandable Sheath |
| Figure 4‑122: Class 2 Device Recall HLS Set Advanced |
| Figure 4‑123: Class 2 Device Recall HLS Set Advanced |
| Figure 4‑124: Class 3 Device Recall Cardiac Assist |
| Figure 4‑125: Class 2 Device Recall TandemHeart Pump |
| Figure 4‑126: Class 1 Device Recall CentriMag Acute Circulatory Support System Motor |
| Figure 4‑127: Class 2 Device Recall Arrow |
| Figure 4‑128: INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study (INVIVITY) |
| Figure 4‑129: Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population |
| Figure 4‑130: PERCEVAL S Valve Clinical Study for Chinese Registration (PERFECT) |
| Figure 4‑131: INSPIRIS RESILIA Valve in Pulmonary Position |
| Figure 4‑132: Trifecta and Epic ViV Detailed Insights into Management Strategies and Outcomes |
| Figure 4‑133: Trifecta™ Long Term Follow-Up (LTFU) Study |
| Figure 4‑134: Post Market Clinical Follow-Up Study in Patients Treated with the On-X Ascending Aortic Prosthesis (AAP) (ASCEND) |
| Figure 4‑135: Regent China Post-Market Clinical Follow-up Study |
| Figure 4‑136: SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy |
| Figure 4‑137: Retrospective Clinical Data Collection on Carbomedics OptiForm Mitral Heart Valve |
| Figure 4‑138: HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve |
| Figure 4‑139: On-X Heart Valve - 17mm Aortic and 23mm Mitral |
| Figure 4‑140: HAART Annuloplasty Device Valve Repair Registry |
| Figure 4‑141: Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study (ARB-PMCF) |
| Figure 4‑142: A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients with Functional Mitral Regurgitation |
| Figure 4‑143: Effectiveness and Durability Long-term Results of Tricuspid Annuloplasty with 3D Shaped Rings |
| Figure 4‑144: PRESERVE-MITRAL Post-Market Registry |
| Figure 4‑145: Transcatheter Mitral Valve InterventiOn Single Center Registry in CHinese Patients with Mitral Valve Disease |
| Figure 4‑146: Valveclip® Transcatheter Mitral Valve Repair Study |
| Figure 4‑147: Caisson Transcatheter Mitral Valve Replacement (TMVR) (INTERLUDE) |
| Figure 4‑148: Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients with Severe Primary Mitral Regurgitation Eligible for High-risk Surgery (MITRA-HR) |
| Figure 4‑149: Mi-thos® Transcatheter Mitral Valve Replacement (First-in-Man Study) |
| Figure 4‑150: MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR (EVOLVE-MR) |
| Figure 4‑151: The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices |
| Figure 4‑152: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population (China XT) |
| Figure 4‑153: The PROTEMBO Trial |
| Figure 4‑154: PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection with the Sentinel™ Device |
| Figure 4‑155: Transcatheter Aortic Valve Replacement (TAVR) Double Balloon Valvuloplasty |
| Figure 4‑156: Mini-invasive Balloon Aortic Valvuloplasty |
| Figure 4‑157: Comparison of Saphenous Vein Harvesting by Endoscopic Versus Open Conventional Methods |
| Figure 4‑158: CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study |
| Figure 4‑159: LVAD Conditioning for Cardiac Recovery |
| Figure 4‑160: EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study |
| Figure 4‑161: Effect of Cardiac Resynchronization Therapy (CRT) on Left Ventricular Assist Device (LVAD) Function |
| Figure 4‑162: The Left Ventricular Assist Device (LVAD) Off or On Pump Implantation Study |
| Figure 4‑163: A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System |
| Figure 4‑164: Outcome of Patients Treated with IABP |
| Figure 4‑165: Intra-aortic Balloon Pump in Extensive Myocardial Infarction with Persistent Ischemia |
| Figure 4‑166: Carmat Total Artificial Heart as a Bridge to Transplant in Patients with Advanced Heart Failure |
| Figure 4‑167: SynCardia 70cc TAH-t for Destination Therapy |
| Figure 4‑168: Syncardia 50cc TAH-t as a Bridge to Transplant |
| Figure 4‑169: Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Cardio Renal Syndrome with Severe Renal Impairment |
| Figure 4‑170: Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™ |
| Figure 4‑171: AMPLATZER PFO Occluder Post Approval Study |
| Figure 4‑172: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study |
| Figure 4‑173: GORE® CARDIOFORM Septal Occluder Migraine Clinical Study |
| Figure 4‑174: Evaluation of the Efficacy and Safety of a Simplified Procedure for the Percutaneous Closure of the Patent Foramen Ovale |
| Figure 4‑175: Amplatzer PFO Occluder Post-marketing Surveillance Study |
| Figure 4‑176: Internal Microstructure of Patent Foramen Ovale Related to Stroke |
| Figure 4‑177: Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes |
| Figure 4‑178: Amplatzer Piccolo Occluder Japan Post-Marketing Database Surveillance |
| Figure 4‑179: Nit-Occlud PDA Post-Approval Study |
| Figure 4‑180: Procedural Outcomes of Percutaneous PDA Closure: Comparative Study between Different Devices |
| Figure 4‑181: A Pilot Study to Assess WATCHMAN FLX™ Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography |
| Figure 4‑182: The ICE WATCHMAN Trial |
| Figure 4‑183: VClip Post-Market Study |
| Figure 4‑184: Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong |
| Figure 4‑185: AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures |
| Figure 4‑186: CentriMag Failure-to-Wean Post Approval Study |
| Figure 4‑187: Quality of Life 1y and 2 y After VV-ECMO for COVID-19 |
| Figure 4‑188: ECMO Treatment of Children in China in the Past 10 Years |
| Figure 4‑189: TandemHeart Experiences and MEthods |
| Figure 4‑190: Retrospective Data Analysis on the Application of Swan-Ganz Catheter in Cardiac Surgery |
| Figure 4‑191: Swan-Ganz Catheter Insertion |
| Figure 5‑1: Cardiac Market by Segment, U.S., 2019 – 2029 (US$M) (1 of 3) |
| Figure 5‑2: Cardiac Market by Segment, U.S., 2019 – 2029 (US$M) (2 of 3) |
| Figure 5‑3: Cardiac Market by Segment, U.S., 2019 – 2029 (US$M) (3 of 3) |
| Figure 5‑4: Leading Competitors, Cardiac Surgery Market, U.S., 2022 (1 of 4) |
| Figure 5‑5: Leading Competitors, Cardiac Surgery Market, U.S., 2022 (2 of 4) |
| Figure 5‑6: Leading Competitors, Cardiac Surgery Market, U.S., 2022 (3 of 4) |
| Figure 5‑7: Leading Competitors, Cardiac Surgery Market, U.S., 2022 (4 of 4) |
| Figure 5‑8: SWOT Analysis, Abbott (1 of 2) |
| Figure 5‑9: SWOT Analysis, Abbott (2 of 2) |
| Figure 5‑10: SWOT Analysis, Abiomed |
| Figure 5‑11: SWOT Analysis, Artivion |
| Figure 5‑12: SWOT Analysis, AtriCure |
| Figure 5‑13: SWOT Analysis, B. Braun |
| Figure 5‑14: SWOT Analysis, Boston Scientific |
| Figure 5‑15: SWOT Analysis, Edwards Lifesciences |
| Figure 5‑16: SWOT Analysis, Getinge |
| Figure 5‑17: SWOT Analysis, LivaNova |
| Figure 5‑18: SWOT Analysis, Medtronic |
| Figure 5‑19: SWOT Analysis, Terumo |
| Figure 6‑1: Procedure Codes Investigated, U.S., 2022 |
| Figure 6‑2: Cardiac Surgery and Heart Valve Procedures by Segment, U.S., 2019 – 2029 (1 of 3) |
| Figure 6‑3: Cardiac Surgery and Heart Valve Procedures by Segment, U.S., 2019 – 2029 (2 of 3) |
| Figure 6‑4: Cardiac Surgery and Heart Valve Procedures by Segment, U.S., 2019 – 2029 (3 of 3) |
| Figure 6‑5: Surgical Heart Valve Procedures by Segment, U.S., 2019 – 2029 |
| Figure 6‑6: Tissue Heart Valve Procedures by Valve Type, U.S., 2019 – 2029 |
| Figure 6‑7: 6.3.2 Tissue Heart Valve Procedures by Tissue Type, U.S., 2019 – 2029 |
| Figure 6‑8: 6.3.3 Tissue Heart Valve Procedures by Device Type, U.S., 2019 – 2029 |
| Figure 6‑9: 6.3.4 Mechanical Heart Valve Procedures by Valve Type, U.S., 2019 – 2029 |
| Figure 6‑10: Mechanical Heart Valve Procedures by Segment, U.S., 2019 – 2029 |
| Figure 6‑11: Annuloplasty Repair Procedures by Valve Type, U.S., 2019 – 2029 |
| Figure 6‑12: Annuloplasty Repair Procedures by Device Type, U.S., 2019 – 2029 |
| Figure 6‑13: Transcatheter Mitral Valve Repair (TMVr) Procedures by Approach, U.S., 2019 – 2029 |
| Figure 6‑14: Transcatheter Mitral Valve Repair (TMVr) Procedures by Disease Type, U.S., 2019 – 2029 |
| Figure 6‑15: Transcatheter Heart Valve Replacement Procedures by Valve Type, U.S., 2019 – 2029 |
| Figure 6‑16: TAVR Procedures by Approach, U.S., 2019 – 2029 |
| Figure 6‑17: TAVR Procedures by Patient Risk Class, U.S., 2019 – 2029 |
| Figure 6‑18: TAVR Procedures by Embolic Protection, U.S., 2019 – 2029 |
| Figure 6‑19: TAVR Procedures by Location, U.S., 2019 – 2029 |
| Figure 6‑20: TAVR Procedures by Valve Type, U.S., 2019 – 2029 |
| Figure 6‑21: TPVR Procedures, U.S., 2019 – 2029 |
| Figure 6‑22: Balloon Valvuloplasty Procedures by Segment, U.S., 2019 – 2029 |
| Figure 6‑23: CABG Procedures by Bypass Type, U.S., 2019 – 2029 |
| Figure 6‑24: CABG Vessel Harvesting Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑25: CABG Procedures by Suture Type, U.S., 2019 – 2029 |
| Figure 6‑26: CABG Procedures by Approach, U.S., 2019 – 2029 |
| Figure 6‑27: Transmyocardial Revascularization Procedures, U.S., 2019 – 2029 |
| Figure 6‑28: Ventricular Assist Device Procedures by Segment, U.S., 2019 – 2029 |
| Figure 6‑29: Percutaneous VAD Procedures by Heart Side, U.S., 2019 – 2029 |
| Figure 6‑30: Percutaneous VAD Procedures by Indication, U.S., 2019 – 2029 |
| Figure 6‑31: Implantable VAD Procedures by Indication, U.S., 2019 – 2029 |
| Figure 6‑32: Implantable VAD Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑33: External VAD Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑34: IABP Procedures by Setting, U.S., 2019 – 2029 |
| Figure 6‑35: IABP Procedures by Device Type, U.S., 2019 – 2029 |
| Figure 6‑36: Heart Transplant Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑37: Remote Hemodynamic Monitoring System Procedures, U.S., 2019 – 2029 |
| Figure 6‑38: Patent Foramen Ovale Closure Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑39: Patent Ductus Arteriosus Device Procedures, U.S., 2019 – 2029 |
| Figure 6‑40: Septal Defect Closure Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑41: ASD Closure Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑42: VSD Closure Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑43: LAA Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑44: Epicardial Device Closure Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑45: Epicardial Clip Procedures by Type, U.S., 2019 – 2029 |
| Figure 6‑46: Extracorporeal Membrane Oxygenation Procedures by Modality, U.S., 2019 – 2029 |
| Figure 6‑47: Extracorporeal Membrane Oxygenation Procedures by Application, U.S., 2019 – 2029 |
| Figure 6‑48: Respiratory Extracorporeal Membrane Oxygenation Procedures by Age Group, U.S., 2019 – 2029 |
| Figure 6‑49: Cardiac Extracorporeal Membrane Oxygenation Procedures by Age Group, U.S., 2019 – 2029 |
| Figure 6‑50: eCPR ECMO Procedures by Age Group, U.S., 2019 – 2029 |
| Figure 7‑1: Tissue Heart Valve Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 7‑2: Total Tissue Heart Valve Market, U.S., 2019 – 2029 |
| Figure 7‑3: Stented Market, U.S., 2019 – 2029 |
| Figure 7‑4: Stentless Market, U.S., 2019 – 2029 |
| Figure 7‑5: Sutureless/Rapid Deployment Market, U.S., 2019 – 2029 |
| Figure 7‑6: Tissue Heart Valve Market by Tissue Type, U.S., 2019 – 2029 (US$M) |
| Figure 7‑7: Leading Competitors, Tissue Heart Valve Market, U.S., 2022 |
| Figure 8‑1: Total Mechanical Heart Valve Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 8‑2: Total Mechanical Heart Valve Market, U.S., 2019 – 2029 |
| Figure 8‑3: Without Conduit Market, U.S., 2019 – 2029 (US$M) |
| Figure 8‑4: With Conduit Market, U.S., 2019 – 2029 |
| Figure 8‑5: Leading Competitors, Mechanical Heart Valve Market, U.S., 2022 |
| Figure 9‑1: Annuloplasty Repair Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 9‑2: Total Annuloplasty Repair Device Market, U.S., 2019 – 2029 |
| Figure 9‑3: Ring Market, U.S., 2019 – 2029 (US$M) |
| Figure 9‑4: Band Market, U.S., 2019 – 2029 |
| Figure 9‑5: Leading Competitors, Annuloplasty Repair Device Market, U.S., 2022 |
| Figure 10‑1: Transcatheter Mitral Valve Repair Market, U.S., 2019 – 2029 |
| Figure 10‑2: Leading Competitors, Transcatheter Mitral Valve Repair Market, U.S., 2022 |
| Figure 11‑1: Transcatheter Heart Valve Replacement Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 11‑2: Total Transcatheter Heart Valve Replacement Market, U.S., 2019 – 2029 |
| Figure 11‑3: Transcatheter Aortic Valve Replacement Market, U.S., 2019 – 2029 |
| Figure 11‑4: Transcatheter Pulmonary Valve Replacement Market, U.S., 2019 – 2029 |
| Figure 11‑5: Leading Competitors, Transcatheter Heart Valve Replacement Market, U.S., 2022 |
| Figure 12‑1: Temporary Pacing and Pressure Measurement Catheter Market, U.S., 2019 – 2029 |
| Figure 12‑2: Leading Competitors, Temporary Pacing and Pressure Measurement Catheter Market, U.S., 2022 |
| Figure 13‑1: Cerebral Embolic Protection Device Market, U.S., 2019 – 2029 |
| Figure 13‑2: Leading Competitors, Cerebral Embolic Protection Device Market, U.S., 2022 |
| Figure 14‑1: Total Balloon Valvuloplasty Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 14‑2: Total Balloon Valvuloplasty Market, U.S., 2019 – 2029 |
| Figure 14‑3: Aortic Market, U.S., 2019 – 2029 |
| Figure 14‑4: Mitral Market, U.S., 2019 – 2029 |
| Figure 14‑5: Pulmonary Market, U.S., 2019 – 2029 |
| Figure 14‑6: Hybrid Market, U.S., 2019 – 2029 |
| Figure 14‑7: Leading Competitors, Balloon Valvuloplasty Market, U.S., 2022 |
| Figure 15‑1: ONCAB Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 15‑2: On-Pump Coronary Artery Bypass Disposables Market by Segment, U.S., 2019 – 2029 (US$M) (1 of 2) |
| Figure 15‑3: ONCAB Disposables Market by Segment, U.S., 2019 – 2029 (US$M) (2 of 2) |
| Figure 15‑4: Total ONCAB Disposables Market, U.S., 2019 – 2029 |
| Figure 15‑5: Oxygenator Market, U.S., 2019 – 2029 |
| Figure 15‑6: Reservoir Market, U.S., 2019 – 2029 |
| Figure 15‑7: Cardioplegia Set Market, U.S., 2019 – 2029 |
| Figure 15‑8: Filter Market, U.S., 2019 – 2029 |
| Figure 15‑9: Pump Head Market, U.S., 2019 – 2029 |
| Figure 15‑10: Bubble Trap Market, U.S., 2019 – 2029 |
| Figure 15‑11: Hemoconcentrator Market, U.S., 2019 – 2029 |
| Figure 15‑12: Custom Tubing Kit Market, U.S., 2019 – 2029 |
| Figure 15‑13: Other Market, U.S., 2019 – 2029 |
| Figure 15‑14: Perfusion System Market, U.S., 2019 – 2029 |
| Figure 15‑15: Leading Competitors, On-Pump Coronary Artery Bypass Device Market, U.S., 2022 |
| Figure 16‑1: Off-Pump Coronary Artery Bypass Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 16‑2: Total Off-Pump Coronary Artery Bypass Device Market, U.S., 2019 – 2029 |
| Figure 16‑3: Stabilizer Device Market, U.S., 2019 – 2029 |
| Figure 16‑4: Positioner Market, U.S., 2019 – 2029 |
| Figure 16‑5: Accessory Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 16‑6: Total Accessory Market, U.S., 2019 – 2029 |
| Figure 16‑7: Blower/Mister Market, U.S., 2019 – 2029 |
| Figure 16‑8: Intracoronary Shunt Market, U.S., 2019 – 2029 |
| Figure 16‑9: Leading Competitors, Off-Pump Coronary Artery Bypass Device Market, U.S., 2022 |
| Figure 17‑1: Autotransfusion Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 17‑2: Autotransfusion Machine Market, U.S., 2019 – 2029 |
| Figure 17‑3: Autotransfusion Machine Installed Base Market, U.S., 2019 – 2029 |
| Figure 17‑4: Autotransfusion Disposables Market, U.S., 2019 – 2029 |
| Figure 17‑5: Leading Competitors, Autotransfusion Device Market, U.S., 2022 |
| Figure 18‑1: Endoscopic Vessel Harvesting Device Market, U.S., 2019 – 2029 |
| Figure 18‑2: Leading Competitors, Endoscopic Vessel Harvesting Device Market, U.S., 2022 |
| Figure 19‑1: Total Anastomosis Assist Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 19‑2: Total Anastomosis Assist Device Market, U.S., 2019 – 2029 |
| Figure 19‑3: Proximal Anastomosis Assist Device Market, U.S., 2019 – 2029 |
| Figure 19‑4: Distal Anastomosis Assist Device Market, U.S., 2019 – 2029 |
| Figure 19‑5: Leading Competitors, Anastomosis Assist Device Market, U.S., 2022 |
| Figure 20‑1: Transmyocardial Revascularization Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 20‑2: Single-Use Fiber-Optic Handpiece Market, U.S., 2019 – 2029 |
| Figure 20‑3: Transmyocardial Revascularization Laser Console Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 20‑4: Leading Competitors, Transmyocardial Revascularization Market, U.S., 2022 |
| Figure 21‑1: Ventricular Assist Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 21‑2: Total Ventricular Assist Device Market, U.S., 2019 – 2029 |
| Figure 21‑3: Percutaneous VAD Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 21‑4: Total Percutaneous VAD Market, U.S., 2019 – 2029 |
| Figure 21‑5: Left Heart Percutaneous VAD Market, U.S., 2019 – 2029 |
| Figure 21‑6: Right Heart Percutaneous VAD Market, U.S., 2019 – 2029 |
| Figure 21‑7: External VAD Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 21‑8: Total External VAD Market, U.S., 2019 – 2029 |
| Figure 21‑9: Short-Term External VAD Market, U.S., 2019 – 2029 |
| Figure 21‑10: Long-Term External VAD Market, U.S., 2019 – 2029 |
| Figure 21‑11: Implantable VAD Market, U.S., 2019 – 2029 (US$M) |
| Figure 21‑12: Implantable VAD Market Unit Analysis, U.S., 2019 – 2029 |
| Figure 21‑13: Leading Competitors, Ventricular Assist Device Market, U.S., 2022 |
| Figure 22‑1: Intra-Aortic Balloon Pump Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 22‑2: Total Intra-Aortic Balloon Pump Market, U.S., 2019 – 2029 |
| Figure 22‑3: Intra-Aortic Balloon Pump Catheter Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 22‑4: Total Intra-Aortic Balloon Pump Catheter Market, U.S., 2019 – 2029 |
| Figure 22‑5: Conventional Intra-Aortic Balloon Pump Catheter Market, U.S., 2019 – 2029 |
| Figure 22‑6: Fiber-Optic Intra-Aortic Balloon Pump Catheter Market, U.S., 2019 – 2029 |
| Figure 22‑7: Intra-Aortic Balloon Pump Console Market, U.S., 2019 – 2029 |
| Figure 22‑8: Leading Competitors, Intra-Aortic Balloon Pump Market, U.S., 2022 |
| Figure 23‑1: Artificial Heart Replacement Device Market, U.S., 2019 – 2029 |
| Figure 23‑2: Leading Competitors, Artificial Heart Replacement Device Market, U.S., 2022 |
| Figure 24‑1: Remote Hemodynamic Monitoring System Market, U.S., 2019 – 2029 |
| Figure 24‑2: Leading Competitors, Remote Hemodynamic Monitoring System Market, U.S., 2022 |
| Figure 25‑1: Patent Foramen Ovale Closure Device Market, U.S., 2019 – 2029 |
| Figure 25‑2: Leading Competitors, Patent Foramen Ovale Closure Device Market, U.S., 2022 |
| Figure 26‑1: Patent Ductus Arteriosus Closure Device Market, U.S., 2019 – 2029 |
| Figure 26‑2: Leading Competitors, Patent Ductus Arteriosus Closure Device Market, U.S., 2022 |
| Figure 27‑1: Atrial Septal & Ventricular Septal Defect Closure Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 27‑2: Total Atrial Septal & Ventricular Septal Defect Closure Device Market, U.S., 2019 – 2029 |
| Figure 27‑3: Atrial Septal Defect Closure Device Market, U.S., 2019 – 2029 |
| Figure 27‑4: Ventricular Septal Defect Closure Device Market, U.S., 2019 – 2029 |
| Figure 27‑5: Leading Competitors, Atrial Septal & Ventricular Septal Defect Closure Device Market, U.S., 2022 |
| Figure 28‑1: Left Atrial Appendage Closure Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 28‑2: Total Left Atrial Appendage Closure Device Market, U.S., 2019 – 2029 |
| Figure 28‑3: Epicardial Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 28‑4: Total Epicardial Device Market, U.S., 2019 – 2029 |
| Figure 28‑5: Epicardial Clip Device Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 28‑6: Open Epicardial Clip Device Market, U.S., 2019 – 2029 |
| Figure 28‑7: MIS Epicardial Clip Device Market, U.S., 2019 – 2029 |
| Figure 28‑8: Epicardial Suture Device Market, U.S., 2019 – 2029 |
| Figure 28‑9: Endocardial Device Market, U.S., 2019 – 2029 |
| Figure 28‑10: Leading Competitors, Left Atrial Appendage Closure Device Market, U.S., 2022 |
| Figure 29‑1: Preshaped Guidewire Market, U.S., 2019 – 2029 |
| Figure 29‑2: Leading Competitors, Preshaped Guidewire Market, U.S., 2022 |
| Figure 30‑1: Extracorporeal Membrane Oxygenation Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 30‑2: Extracorporeal Membrane Oxygenation Machine Market, U.S., 2019 – 2029 |
| Figure 30‑3: Extracorporeal Membrane Oxygenation Disposables Market by Segment, U.S., 2019 – 2029 (US$M) |
| Figure 30‑4: Total Extracorporeal Membrane Oxygenation Disposables Market, U.S., 2019 – 2029 |
| Figure 30‑5: Venovenous Market, U.S., 2019 – 2029 |
| Figure 30‑6: Venoarterial Market, U.S., 2019 – 2029 |
| Figure 30‑7: Arteriovenous Market, U.S., 2019 – 2029 |
| Figure 30‑8: Leading Competitors, Extracorporeal Membrane Oxygenation Market, U.S., 2022 |
By 2029, the U.S. cardiac surgery market is poised for remarkable expansion. This surge is primarily propelled by two key factors: the advancing age of the population and the escalating prevalence of cardiovascular ailments nationwide. Notably, a considerable patient base exists for a multitude of cardiac surgery devices applications.
